Institution
University of Saint Mary
Education•Leavenworth, Kansas, United States•
About: University of Saint Mary is a education organization based out in Leavenworth, Kansas, United States. It is known for research contribution in the topics: Population & Galaxy. The organization has 2276 authors who have published 2399 publications receiving 58990 citations. The organization is also known as: University of St. Mary & University of St Mary.
Topics: Population, Galaxy, Active galactic nucleus, Cancer, Health care
Papers published on a yearly basis
Papers
More filters
••
TL;DR: The goal of this paper is to describe the characteristics of cutaneous manifestations of systemic AL amyloidosis associated with MM according to age, sex, race, Ig type, plasma cell percentage, and cytogenetic and fluorescent in situ hybridization studies along with their outcomes.
20 citations
••
TL;DR: This is the first report identifying important, differentially expressed genes during ischemic preconditioning in Nox2−/− mice by using microarray analysis.
Abstract: Several potential sources of reactive oxygen species (ROS) in cells exist. One source is NADPH oxidase, which is especially important for superoxide radical production. Nox2 is a primary regulatory subunit of NADPH oxidase. In the present study, we examined the role of ROS and NADPH oxidase in ischemic preconditioning (IP)-mediated cardioprotection by using Nox2−/− mice. Both wild-type (WT) and Nox2−/− mice were subjected to either 30 min of ischemia followed by 2 h of reperfusion (IR) or IP prior to 30 min ischemia and 2 h of reperfusion. Reduction in left ventricular developed pressure (60.1 versus 63 mmHg), dp/dt
max (893 versus 1,027 mmHg/s), and aortic flow (0.9 versus 1.8 ml/min) was observed in Nox2−/−IPIR compared to WTIPIR along with increased infarct size (33% versus 22%) and apoptosis after 120 min of reperfusion. Differentially regulated genes were demonstrated by comparing gene expression in WTIPIR versus Nox2−/− IPIR hearts. Selected differentially regulated genes such as β-catenin, SRPK3, ERDR1, ACIN1, Syntaxin-8, and STC1 were validated by real-time PCR. Taken together, this is the first report identifying important, differentially expressed genes during ischemic preconditioning in Nox2−/− mice by using microarray analysis.
20 citations
••
TL;DR: The results suggest that, in teeth, there is variation in the degree of sexual dimorphism between populations and discriminant functions for sex estimation in dentition are population specific.
20 citations
••
TL;DR: In this paper, the authors investigated the impact of impulsivity on sexual homicide and found that sexual murderers present personal characteristics that differ from non-homicide offenders, even the violent ones, and it is important to continue investigating this line of inquiry.
20 citations
••
TL;DR: In the naturalistic setting, symptomatically stable outpatients with schizophrenia who were switched to aripiprazole showed clinically meaningful treatment benefits and there were no significant between-group differences in time to failure to maintain remission and time to dropout.
Abstract: The objectives of this 12-week multicenter open-label switching study were to evaluate the overall clinical efficacy, safety, and tolerability of aripiprazole in stable patients with schizophrenia or schizoaffective disorder, and to assess, in a naturalistic setting, whether such patients experience symptom worsening when switched from D2 receptor antagonists to aripiprazole (a D2 receptor partial agonist). Patients with schizophrenia or schizoaffective disorder in a symptomatically stable state were randomized to aripiprazole or standard-of-care antipsychotics. The Clinical Global Impression (CGI), Positive and Negative Syndrome Scale, and Investigator's Assessment Questionnaire were used monthly. The Udvalg for Kliniske Undersogelser side-effect rating scale scores and treatment emergent adverse events were recorded to assess the safety and tolerability of switching to aripiprazole from other antipsychotics. A total of 292 patients were randomly assigned to receive aripiprazole (N = 245) or non-aripiprazole antipsychotics (N = 47). Mean CGI-Improvement score at 12 weeks was 3.56+/-1.29 (95% confidence interval: 3.39-3.73) in the aripiprazole group, indicating that aripiprazole was effective in treating schizophrenic patients. Aripiprazole treatment resulted in improvement from baseline on all efficacy outcome measures, including Positive and Negative Syndrome Scale total, positive, negative, and general subscale, and CGI-Severity scores. In addition, after aripiprazole treatment, the remission rate was increased from 43.9% at baseline to 51.7% at 12 weeks. The proportion of patients with symptom worsening at 12 weeks was low (12.4%). Both Investigator's Assessment Questionnaire and Udvalg for Kliniske Undersogelser scores showed that there were fewer prolactin-related adverse events in the aripiprazole group than in the standard-of-care antipsychotics group (P<0.05). There were no significant between-group differences in time to failure to maintain remission and time to dropout. In the naturalistic setting, symptomatically stable outpatients with schizophrenia who were switched to aripiprazole showed clinically meaningful treatment benefits. The majority of patients was successfully switched from other antipsychotics without serious symptom exacerbation or adverse events over a course of 12 weeks.
20 citations
Authors
Showing all 2277 results
Name | H-index | Papers | Citations |
---|---|---|---|
David R. Holmes | 161 | 1624 | 114187 |
Jeremy K. Nicholson | 141 | 773 | 80275 |
Shaun Purcell | 120 | 326 | 132973 |
Brad K. Gibson | 94 | 564 | 38959 |
Andrew N. Nicolaides | 90 | 572 | 30861 |
Mark D. Fleming | 81 | 433 | 36107 |
Jill Clayton-Smith | 74 | 308 | 19168 |
Alejandro A. Rabinstein | 72 | 725 | 33802 |
Philip B. Gorelick | 70 | 297 | 26424 |
Lucien C. Manchester | 67 | 113 | 18924 |
Elizabeth Murphy | 66 | 259 | 16966 |
Graeme C.M. Black | 64 | 274 | 15554 |
Raul Urrutia | 60 | 293 | 11664 |
Jane McCusker | 59 | 220 | 11538 |
Christopher J. Mathias | 58 | 278 | 16171 |